logo
When should I see a doctor for sunburn?

When should I see a doctor for sunburn?

Globe and Mail5 hours ago
Ask a Doctor is a series of physician-authored columns offering insights and advice on common health topics. It is not a substitute for seeking medical care.
As an emergency doctor, I've seen plenty of people come to the hospital with painful sunburns – sometimes severe enough to need medical care. Many of these patients were surprised by how quickly their skin turned red after an afternoon gardening or a walk in the park.
While most sunburns can be treated at home, some symptoms warrant a closer look. Here's what to do if you've already experienced sunburn – and how to protect your skin from sun exposure.
Sunburn is a type of radiation burn from excessive exposure to ultraviolet (UV) rays. Your skin reacts with inflammation that ranges from varying degrees of redness and pain to blisters and peeling. Here's what you can do to help:
If you notice any of the following, seek medical care right away:
There are two main types of UV rays: UVA and UVB. Both cause damage to skin components and DNA, leading to tanning, burns, accelerated aging and an increased risk of skin cancer over time.
You don't have to experience sunburn to sustain damage and even a single sunburn increases your lifetime risk of skin cancer. A tan also means injury, since your skin darkens in response to UV exposure to protect itself. That increased melanin production is actually a sign that DNA damage has already occurred.
Sunburns and bug bites are summer rites, but you can minimize the feeling of irritation
In Canada, UV levels peak between late spring and early fall, and are usually highest between 11 a.m. and 3 p.m., but UV rays don't stop outside these hours or seasons. Cloud cover does not block all UV; up to 80 per cent of rays can still reach you on overcast days. And harmful sunlight can also reach through windows or in your vehicle.
If you will be spending time outside, it's important to use a sunscreen with broad-spectrum protection that shields against both UVA and UBV rays. Pay attention to the sun-protection factor or SPF number. The Canadian Dermatology Association recommends sunscreen with a SPF 30 or higher.
Make sure to apply sunscreen generously 15 to 20 minutes before exposure. Be sure to reapply every two hours, and more often if sweating or swimming, and don't forget ears, neck, feet and scalp lines. For your lips, choose an SPF 30 or more lip balm, and reapply every hour.
Most people don't use enough sunscreen for it to be effective. Health Canada recommends adults use about a teaspoon of sunscreen to cover each area of exposed skin (e.g. a teaspoon for each arm). For just the face and neck, aim for about 1/2 a teaspoon.
Spray sunscreens are popular because of their ease of application, but it's difficult to know whether enough has been applied. If using a spray sunscreen, apply liberally until the skin is glistening, then rub the sunscreen in to get even coverage. For the head and neck, do not spray directly onto it to avoid inhaling the spray. Instead, spray a large amount onto your hands, then rub onto your face, ears and neck.
Looking for sunscreen advice? Listen to the experts, not social media
But remember that sunscreen alone won't protect you. Here's what I tell my patients:
Dr. Shazma Mithani is an emergency physician working with adult and pediatric patients in Edmonton. Dr. Mithani is actively involved with the Canadian Medical Association, Alberta Medical Association and Sexual Assault Centre of Edmonton. She is also co-host of The Doc Talk Podcast.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer
MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer

Globe and Mail

time15 minutes ago

  • Globe and Mail

MRK's ADC Candidate Gets FDA Breakthrough Therapy Tag for Lung Cancer

Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), for treating adult patients with extensive-stage small cell lung cancer whose disease progressed on or after platinum-based chemotherapy. The FDA's Breakthrough Therapy designation is a process that speeds up the development and review of drugs for serious or life-threatening conditions. This designation is granted when early clinical evidence suggests that a drug may significantly improve over existing treatments on one or more important clinical measures. The FDA's latest decision was based on data from the phase II IDeate-Lung01 study with support from the phase I/II IDeate-PanTumor01 study. The IDeate-Lung01 study evaluated the safety and efficacy of I-DXdin in the given patient population. MRK Stock Performance Year to date, shares of Merck have plunged 15.3% compared with the industry 's decline of 2.8%. MRK & Daiichi's Deal for I-DXd & Other ADC Candidates Besides extensive-stage small cell lung cancer, I-DXd is being evaluated in separate phase III studies for treating esophageal cancer and prostate cancer. Developed by Daiichi Sankyo, this ADC drug candidate already enjoys an orphan drug designation for treating small-cell lung cancer in the United States, Europe and some other countries. Merck acquired global co-development and co-commercialization rights to I-DXd and two other ADCs, patritumab deruxtecan and raludotatug deruxtecan, from Daiichi Sankyo in October 2023 for a total potential consideration of up to $22 billion. However, Daiichi Sankyo has retained exclusive rights for the development of the candidates in Japan. In August last year, Merck expanded the collaboration to co-develop and co-commercialize MK-6070, an investigational T-cell engager targeting delta-like ligand 3 (DLL3), which it obtained from its recent acquisition of Harpoon Therapeutics. Patritumab deruxtecan is being developed in late-stage studies for breast cancer, while raludotatug deruxtecan is being developed in mid-stage studies for ovarian cancer as well as other cancer indications. Competition in the ADC Space ADCs are being considered a disruptive innovation in the pharmaceutical industry, as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors. Daiichi Sankyo has several ADCs in clinical development across multiple types of cancer. It markets Enhertu, a HER2-directed ADC, in partnership with AstraZeneca AZN, which is presently approved across multiple indications, including HER2-mutated breast, lung and gastric cancers. In January 2025, the FDA approved AZN and Daiichi's second ADC drug, Datroway, for treating unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy. The FDA approved Datroway for its second indication, non-small-cell lung cancer, in June. Pfizer PFE also forayed into the lucrative ADC space with the acquisition of Seagen for $43 billion in late 2023. Following this acquisition, PFE added three ADCs to its portfolio — Adcetris, Padcev, Tukysa and Tivdak — all approved across various types of solid tumors and hematologic malignancies. These products contributed meaningfully to Pfizer's revenues in 2024 and in the first half of 2025. MRK's Zacks Rank Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report

IC-MPGN Therapeutics Market Expected to Grow With Complement Inhibitor Therapies: First FDA Approvals, Clinical Pipeline
IC-MPGN Therapeutics Market Expected to Grow With Complement Inhibitor Therapies: First FDA Approvals, Clinical Pipeline

Globe and Mail

time32 minutes ago

  • Globe and Mail

IC-MPGN Therapeutics Market Expected to Grow With Complement Inhibitor Therapies: First FDA Approvals, Clinical Pipeline

"Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Insights, Epidemiology, and Market Forecast – 2034" The IC-MPGN market, valued at USD 12M in the US in 2023, is set to grow significantly by 2034, with ~7K cases across the 7MM. Novartis Pharmaceuticals and Apellis Pharmaceuticals lead innovation with iptacopan (LNP023) and pegcetacoplan (APL-2/EMPAVELI). In Aug 2025, the FDA approved Apellis' EMPAVELI as the first IC-MPGN therapy, marking a major milestone in treating this ultra-rare kidney disease. DelveInsight's ' Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Market Insights, Epidemiology, and Market Forecast – 2034 ' report delivers a comprehensive analysis of the IC-MPGN market, covering historical and forecasted patient pools, current treatment practices, emerging drugs, and market size trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Key Takeaways Market size projection: As per DelveInsight's analysis, the total market size of IC-MPGN in the 7MM is expected to surge significantly by 2034, with the United States market alone growing significantly from approximately USD 12 million in 2023. Patient population data: The report provides the total IC-MPGN potential pool of more than 7K diagnosed prevalent cases across the 7MM in 2023, with the United States representing about 55% of these cases at approximately 3,770 diagnosed patients. Key companies: Leading IC-MPGN companies, such as Novartis Pharmaceuticals, Apellis Pharmaceuticals, and others, are driving innovation in this ultra-rare kidney disease therapeutic area. Pipeline assets: Some of the key IC-MPGN pipeline therapies include Iptacopan (LNP023) from Novartis, Pegcetacoplan (APL-2) from Apellis Pharmaceuticals, and others targeting complement pathway inhibition. In August 2025, the FDA approved pegcetacoplan (EMPAVELI) by Apellis Pharmaceuticals as the first treatment specifically for patients 12 years and older with primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The approval was based on the Phase 3 VALIANT trial (NCT05067127), which demonstrated significant clinical benefits. Furthermore, Iptacopan (LNP023) is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase 3 study specifically for idiopathic IC-MPGN. Discover recent advancements in the IC-MPGN treatment landscape @ IC-MPGN Recent Developments. IC-MPGN Market Dynamics The IC-MPGN market represents an ultra-rare therapeutic area with significant unmet medical needs and substantial growth potential. Currently valued at approximately USD 12 million in the United States in 2023, the market is characterized by the lack of approved medications specifically indicated for IC-MPGN, creating a substantial demand for treatments that address the root cause of this progressive kidney disease. IC-MPGN market drivers include increasing awareness of complement-mediated diseases, advances in understanding the pathophysiology of IC-MPGN, and the development of targeted complement inhibitors. The FDA approval of pegcetacoplan (EMPAVELI) by Apellis Pharmaceuticals, the first drug specifically approved for IC-MPGN heightens the optimisim in this landscape, further propelling the market. The disease is characterized by immune complex deposition in the glomeruli, triggering inflammation and damage that can lead to kidney failure within 5-10 years of diagnosis. Current treatment strategies involve supportive measures with or without traditional immunosuppression, showing limited effectiveness in slowing disease progression. IC-MPGN epidemiology includes moe than 7K diagnosed prevalent cases across the 7MM, with adults representing about 90% of all cases, typically resulting from chronic infections, autoimmune disorders, or underlying conditions such as hepatitis C, systemic lupus erythematosus (SLE), or monoclonal gammopathy. Clinical development activity is intensifying, with key assets advancing through Phase III trials. The IC-MPGN emerging therapies centers on targeted complement inhibition, addressing the underlying pathophysiology of IC-MPGN. The IC-MPGN competitive landscape features established pharmaceutical companies leveraging their expertise in nephrology and complement biology. Currently the market currently relies heavily on off-label prescription medications, creating opportunities for companies developing targeted therapies. However, challenges exist in developing effective complement inhibitors due to the complexity of the complement system and its adaptive capabilities. Furthermore, the IC-MPGN market outlook remains positive, driven by the anticipated launch of targeted therapies, increasing diagnosis rates, and growing recognition of complement-mediated kidney diseases. The market is expected to experience significant growth through 2034, supported by the entry of novel therapeutics that address the underlying disease mechanisms rather than merely providing symptomatic relief. Download the IC-MPGN Market report to understand which factors are driving the therapeutic market @ IC-MPGN Market Trends. IC-MPGN Epidemiology The IC-MPGN epidemiology across the 7MM reveals a rare but significant patient population requiring specialized therapeutic intervention. In 2023, more 7K diagnosed prevalent cases were identified across the seven major markets, representing a substantial patient population affected by this ultra-rare kidney disease. The United States dominates the global patient population, accounting for approximately 55% of all cases with around 3,770 diagnosed patients, followed by Japan as the second-largest market. The IC-MPGN epidemiology geographic distribution shows notable variations across the 7MM regions. Within the EU4 countries and the United Kingdom, Germany represents the largest patient population, followed by Spain, while Italy demonstrates the lowest number of cases. This distribution pattern reflects both demographic factors and potentially differential diagnostic capabilities across these regions. Japan shows a distinct age distribution pattern, with adults being significantly more prevalent compared to the pediatric population, consistent with the global trend of adult predominance in IC-MPGN cases. The IC-MPGN epidemiology age-specific segmentation reveals that approximately 90% of all IC-MPGN cases occur in adults, primarily due to underlying conditions that develop over time, including chronic infections, autoimmune disorders, hepatitis C, systemic lupus erythematosus, and monoclonal gammopathy. These conditions lead to persistent immune complex formation, triggering complement system activation and resulting in progressive kidney damage. The pediatric population represents a smaller but clinically significant segment requiring specialized care approaches. Additionally, DelveInsight's gender-specific analysis indicates a relatively balanced distribution between male and female patients, though specific regional variations exist across the 7MM. The total treated cases represent a subset of the diagnosed prevalent population, reflecting current treatment limitations and the challenge of managing this progressive disease with existing therapeutic options. The forecast period from 2024 to 2034 anticipates gradual growth in diagnosed cases, driven by improved awareness, enhanced diagnostic capabilities, and better recognition of IC-MPGN as a distinct clinical entity separate from other forms of membranoproliferative glomerulonephritis. Discover evolving trends in the IC-MPGN patient pool forecasts @ IC-MPGN Epidemiology Analysis. Key IC-MPGN Companies and Treatment Market The clinical and regulatory IC-MPGN landscape is evolving rapidly, with current treatment options limited to supportive care and off-label immunosuppressive therapies. Traditional approaches include renin-angiotensin-aldosterone system inhibitors, immunosuppressants such as corticosteroids, calcineurin inhibitors, and mycophenolate mofetil-based treatments, though these show limited effectiveness in slowing disease progression. The limited IC-MPGN approved therapies has created a significant treatment gap that emerging complement inhibitors aim to address. The IC-MPGN clinical pipeline activity is concentrated around complement pathway modulation, with two leading companies advancing promising therapeutics through late-stage development. Key players include Novartis Pharmaceuticals (stock symbol: NVS) with iptacopan (LNP023) and Apellis Pharmaceuticals (stock symbol: APLS) with pegcetacoplan (APL-2), both targeting different aspects of the complement cascade to address the underlying pathophysiology of IC-MPGN. Market positioning of these pipeline assets represents a paradigm shift from symptomatic management to targeted disease modification. Iptacopan functions as an investigational, first-in-class, orally administered factor B inhibitor of the alternative complement pathway, discovered at the Novartis Institutes for BioMedical Research. Currently in Phase III clinical development, the drug has the potential to become the first targeted therapy to delay progression to dialysis in complement-related kidney diseases. Pegcetacoplan operates as a targeted C3 inhibitor designed to regulate excessive complement activation, utilizing a unique 15-amino acid cyclic peptide conjugated to polyethylene glycol that binds to C3 and C3b, directly preventing activation of C3, C5, and the alternative pathway. Commercial arrangements include strategic collaborations, with Apellis partnering with Sobi for the VALIANT study results announcement. Both companies have established comprehensive development programs spanning multiple complement-related diseases, positioning their assets for potential label expansions beyond IC-MPGN. The regulatory pathway for these novel therapies benefits from the rare disease designation and the significant unmet medical need, potentially facilitating accelerated development timelines and priority review processes. Discover which companies are innovating in the IC-MPGN treatment landscape @ IC-MPGN Competitive Landscape. Conclusion DelveInsight's comprehensive analysis of the IC-MPGN market reveals a therapeutic area poised for transformation through targeted complement inhibition. With approximately 7,100 patients across the 7MM currently lacking effective treatment options, the anticipated market growth driven by iptacopan and pegcetacoplan represents a significant advancement for this ultra-rare kidney disease. The convergence of improved understanding of complement-mediated pathophysiology, positive late-stage clinical results, and the substantial unmet medical need positions the IC-MPGN market for meaningful expansion through 2034. As these innovative therapies progress toward regulatory approval and commercial launch, they offer the potential to fundamentally change the treatment paradigm and improve outcomes for patients suffering from this progressive and debilitating condition. Table of Contents 1. Key Insights 2. Executive Summary of IC-MPGN 3. Competitive Intelligence Analysis for IC-MPGN 4. IC-MPGN Market Overview at a Glance 5. IC-MPGN: Disease Background and Overview 6. IC-MPGN Patient Journey 7. IC-MPGN Epidemiology and Patient Population 8. Treatment Algorithm, Current Treatment, and Medical Practices 9. IC-MPGN Unmet Needs 10. Key Endpoints of IC-MPGN Treatment 11. IC-MPGN Marketed Products 12. IC-MPGN Emerging Therapies 13. IC-MPGN: Seven Major Market Analysis 14. Attribute analysis 15. 7MM: Market Outlook 16. Access and Reimbursement Overview of IC-MPGN 17. KOL Views 18. IC-MPGN Market Drivers 19. IC-MPGN Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer 23. About DelveInsight About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Arpit Anand Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:

Nutriband (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20
Nutriband (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20

Globe and Mail

time33 minutes ago

  • Globe and Mail

Nutriband (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20

Nutriband (NASDAQ: NTRB) announced it will participate in the Emerging Growth Conference on August 20, 2025. Chairman Serguei Melnik will deliver a live, interactive presentation and may open the floor for real-time questions from shareholders and the investment community. To view the full article, visit About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire Austin, Texas 512.354.7000 Office Editor@ BioMedWire is powered by IBN

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store